DDIT3 and diffuse large B-cell lymphoma: To test the effect of venetoclax in combination with chemotherapy, a study (NCT02055820) of venetoclax in combination with R-CHOP or obinutuzumab plus CHOP (G-CHOP) in previously untreated DLBCL was performed, and the results demonstrated an ORR of 87.5% (CR 79.2%) in the venetoclax plus R-CHOP group and an ORR of 87.5% (CR 78.1%) in the venetoclax plus G-CHOP group.